Prelude Therapeutics Q2 2024 GAAP EPS $(0.46) Misses $(0.40) Estimate. Cash And Equivalents $179.8M
Portfolio Pulse from Benzinga Newsdesk
Prelude Therapeutics (NASDAQ:PRLD) reported a Q2 2024 GAAP EPS of $(0.46), missing the analyst consensus estimate of $(0.40) by 15%. Despite the miss, this represents a 14.81% improvement over the $(0.54) loss per share from the same period last year. The company has $179.8M in cash and equivalents.
August 12, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Prelude Therapeutics reported a Q2 2024 GAAP EPS of $(0.46), missing the analyst estimate of $(0.40) by 15%. However, the loss per share improved by 14.81% YoY. The company has $179.8M in cash and equivalents.
The miss on EPS estimates is likely to have a negative short-term impact on the stock price. However, the improvement in losses YoY and strong cash position may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100